Shionogi Reports ¥163.3 Billion in First-Quarter Revenue, Keeps FY2026 Outlook
Key Facts
Shionogi kept its FY2026 forecasts at ¥700 billion in revenue, ¥220 billion in operating profit and ¥210 billion in profit attributable to owners of the parent, according to the company’s financial results page. The figures come as the company’s investor relations calendar listed the announcement of its second-quarter results for October 29, 2026, at 1:00 p.m. Japan time. However, the published annual guidance does not confirm a new forecast increase on that date. In the available first-quarter information, the company said it was maintaining its annual forecasts unchanged. The page also shows expected annual dividends, not a confirmed announcement of a new increase alongside the second-quarter results.
The company reported revenue of ¥163.3 billion in the first quarter of FY2026, up 63.7% year on year. Operating profit was ¥66.9 billion, up 90.6% from the same period. Profit attributable to owners of the parent reached ¥97.7 billion, an annual increase of 148.2%. The results show profits growing faster than revenue during the quarter, while full-year targets remained at their published levels. In FY2025, Shionogi posted revenue of ¥499.677 billion, up 14.0%, and operating profit of ¥166.725 billion, up 6.5%.
Shionogi attributed first-quarter revenue growth mainly to the consolidation of Torii Pharmaceutical, the transfer of the edaravone business and higher royalty revenue, particularly related to its HIV business. By source of increase, domestic prescription drug sales added ¥19.4 billion compared with the first quarter of FY2025. Overseas subsidiaries and exports contributed ¥28.0 billion, while royalty revenue increased by ¥16.2 billion. These contributions show that revenue growth came through several operational and commercial channels, alongside changes in the scope of the business. The company described the growth drivers as including “the consolidation of Torii Pharmaceutical, the transfer of the edaravone business, and an increase in royalty revenue centered on the HIV business.”
The FY2026 forecasts published in May indicated expected annual growth of 40.1% in revenue and 32.0% in operating profit, compared with 2.4% for profit attributable to owners of the parent. The company set its revenue forecast at ¥700 billion, operating profit at ¥220 billion and net profit attributable to owners of the parent at ¥210 billion. The available comparison is therefore between strong first-quarter performance and the announced full-year targets, with no published confirmation that those targets were revised in the October 29 announcement. FY2025 provides the basis for these forecasts: the year ended on March 31, 2026, with revenue of ¥499.677 billion and operating profit of ¥166.725 billion. The available figures here do not include the second-quarter results or revised annual guidance.
Under its dividend policy, Shionogi expects to pay ¥76 per share for FY2026, comprising an interim dividend of ¥38 and a final dividend of ¥38. The expected total is ¥5 higher than the ¥71 per share distributed in FY2025. The company says its policy, as part of its STS2030 plan review, targets a dividend-on-equity ratio of 4.0%. These levels are part of the company’s published forecasts and do not by themselves confirm an announcement of a new increase on the day of the second-quarter results. SGIOF shares, meanwhile, closed at $17.05 on October 28, compared with $18 on October 27, according to EL7 data, which does not specify a link between the price movement and the results announcement.
The investor relations calendar listed a research and development meeting on November 18, 2026, the next recorded corporate event after the second-quarter results announcement. The meeting is part of the company’s follow-up on its research activities after presenting its financial results. The company had set the second-quarter results announcement for October 29 at 1:00 p.m. Japan time. Published annual forecasts remain at ¥700 billion in revenue, ¥220 billion in operating profit and ¥210 billion in profit attributable to owners of the parent. FY2026 dividends also remain at ¥76 per share on the page, pending any subsequent official update.